Eli Lilly & Company is investing approximately $700 million to create the Institute for Genetic Medicine in Boston. Located in the Seaport district, the leased facility will provide 334,000 rsf of leading-edge research space for the discovery of innovative RNA and DNA-based therapies. The project will also include a shared R&D center with dedicated and configurable lab environments to enable biotech start-ups to collaborate with Lilly scientists.
The Institute for Genetic Medicine will be housed in a 12-story building that will be constructed, owned, and managed by Alexandria Real Estate Equities. Prioritizing employee health and wellbeing, the amenity-rich structure will feature green terraces with flexible work zones and a dynamic rooftop deck. Connecting occupants and visitors to an expansive waterfront experience of pedestrian paths and public art, the ground floor will house numerous dining and retail venues, a lounge, and a community touchdown area. The sustainably designed facility will leverage geothermal technologies, efficient mechanical systems, a high-performance envelope, and a photovoltaic array to achieve exceptional energy performance. A resilient design proactively addresses climate risk by elevating site grades and landscape elements above future flood levels. The development is targeting LEED Gold Core & Shell, Fitwel, WELL, and WiredScore Platinum certifications. Construction began in 2021 and occupancy is expected in late 2023.
